Pre-commercialization of circadian clock-drug interactions screening tool for therapeutic applications
The CIRCOMMUNICATION project aims to commercialize CircaSCOPE, a high-throughput method for constructing Phase Transition Curves to enhance drug efficacy and minimize side effects through chronotherapy.
Projectdetails
Introduction
Circadian clocks carry immense importance to human health, as clock disruption is related to various malignancies from sleep disorders through diabetes to cancer. Furthermore, many drug targets are influenced by circadian clocks. In order to maximize a drug’s efficacy while minimizing side effects, it is necessary to consider the drug’s time-of-administration, also known as “chronotherapy.” These revelations are critical for drug administration and development.
Challenges in Implementation
However, their practical implementation is tempered by the lack of suitable research tools that bridge the gap from the bench to the clinic. The time-dependent effect of an intervention on the clock is represented by the Phase Transition Curve (PTC). PTC retrieval is laborious and challenging; consequently, they were mostly overlooked in the pharmaceutical R&D process.
Project Overview
In the ERC Project CIRCOMMUNICATION, we studied clock-resetting mechanisms, which led to the development of CircaSCOPE, an efficient high-throughput methodology for high-resolution PTC construction. CircaSCOPE can be used as a powerful screening method for clock-modulating drugs, either for the purpose of:
- Targeting pathologies associated with circadian disruption
- Identifying drugs which elicit unwanted side effects on the clock
Once fully developed and systematically integrated into chrono-medicine, CircaSCOPE has the potential to improve drug discovery and yield medicines with a better therapeutic index.
Commercialization Plan
Here, we detail our plan for the first steps toward the commercialization of our innovation. We will demonstrate the applicability of this approach through drug library screens and expand the repertoire of cell types that the system relies on.
Future Directions
In addition, we will explore different commercialization strategies and interact with potential stakeholders and end-users. Given the medical importance of circadian effects, we envision that CircaSCOPE will become a gold-standard procedure in future drug development.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 150.000 |
Totale projectbegroting | € 150.000 |
Tijdlijn
Startdatum | 1-4-2022 |
Einddatum | 30-9-2023 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- WEIZMANN INSTITUTE OF SCIENCEpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Targeting the circadian clock in personalized disease preventionThis project aims to identify and mitigate health risks associated with disrupted circadian rhythms in night workers through genetic profiling and targeted interventions for healthier aging. | ERC Advanced... | € 2.499.965 | 2022 | Details |
Co-option of host circadian rhythms in cancerINN-TIME aims to uncover how tumors exploit circadian rhythms of innate immune and stromal cells to evade anti-tumoral defenses, paving the way for novel cancer therapies. | ERC Starting... | € 1.500.000 | 2024 | Details |
The early ticking of the central circadian pacemaker: when and howStarTicking aims to uncover the development and functionality of the circadian clock in mice and humans, linking early environmental factors to behavioral outcomes in pre-term infants. | ERC Consolid... | € 1.955.875 | 2024 | Details |
Circadian rhythm: from preclinical to post-diagnosis dementiaThe RHYTHM IN DEMENTIA project aims to identify circadian rhythm features linked to dementia risk and progression, using accelerometry and biomarkers to inform prevention strategies. | ERC Consolid... | € 1.999.982 | 2023 | Details |
Accurate quantification of neurologic disease over timeThe project aims to develop CHRONOS, an AI-driven diagnostic tool using synthetic biomaps to enable earlier and more accurate detection of brain tumors, facilitating timely clinical decisions. | ERC Proof of... | € 150.000 | 2025 | Details |
Targeting the circadian clock in personalized disease prevention
This project aims to identify and mitigate health risks associated with disrupted circadian rhythms in night workers through genetic profiling and targeted interventions for healthier aging.
Co-option of host circadian rhythms in cancer
INN-TIME aims to uncover how tumors exploit circadian rhythms of innate immune and stromal cells to evade anti-tumoral defenses, paving the way for novel cancer therapies.
The early ticking of the central circadian pacemaker: when and how
StarTicking aims to uncover the development and functionality of the circadian clock in mice and humans, linking early environmental factors to behavioral outcomes in pre-term infants.
Circadian rhythm: from preclinical to post-diagnosis dementia
The RHYTHM IN DEMENTIA project aims to identify circadian rhythm features linked to dementia risk and progression, using accelerometry and biomarkers to inform prevention strategies.
Accurate quantification of neurologic disease over time
The project aims to develop CHRONOS, an AI-driven diagnostic tool using synthetic biomaps to enable earlier and more accurate detection of brain tumors, facilitating timely clinical decisions.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Leveraging CRISPR-Cas for fast and accurate point-of-care diagnosticsScope Biosciences aims to validate its patented CRISPR-Cas diagnostic technology, scopeDx, for rapid, accurate, and adaptable point-of-care diagnostics in healthcare. | EIC Transition | € 2.498.125 | 2024 | Details |
Artificial Intelligence Chrono SunglassesHet project ontwikkelt AI Chrono Zonnebrillen voor Parkinson-patiënten om lichttherapie te optimaliseren en hun kwaliteit van leven te verbeteren. | Mkb-innovati... | € 350.000 | 2021 | Details |
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug developmentCherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing. | EIC Accelerator | € 2.499.831 | 2024 | Details |
Voorkomen van therapieresistentie bij kankerDit project onderzoekt een bloedgebaseerde methode voor vroege detectie van therapieresistentie bij kanker om levensverwachting te verbeteren. | Mkb-innovati... | € 20.000 | 2021 | Details |
Bringing 3D cardiac tissues to high throughput for drug discovery screensDeveloping a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability. | EIC Transition | € 1.457.500 | 2023 | Details |
Leveraging CRISPR-Cas for fast and accurate point-of-care diagnostics
Scope Biosciences aims to validate its patented CRISPR-Cas diagnostic technology, scopeDx, for rapid, accurate, and adaptable point-of-care diagnostics in healthcare.
Artificial Intelligence Chrono Sunglasses
Het project ontwikkelt AI Chrono Zonnebrillen voor Parkinson-patiënten om lichttherapie te optimaliseren en hun kwaliteit van leven te verbeteren.
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug development
Cherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing.
Voorkomen van therapieresistentie bij kanker
Dit project onderzoekt een bloedgebaseerde methode voor vroege detectie van therapieresistentie bij kanker om levensverwachting te verbeteren.
Bringing 3D cardiac tissues to high throughput for drug discovery screens
Developing a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability.